The HGF/SF antagonist NK4 reverses fibroblast- and HGF-induced prostate tumor growth and angiogenesis in vivo

International Journal of Cancer

Volumn 106, Issue 3, 2003, Pages 348-354

  Davies, Gaynor ^a   Mason, Malcolm D ^b   Martin, Tracey A ^a   Parr, Christian ^a   Watkins, Gareth ^a   Lane, Jane ^a   Matsumoto, Kunio ^c   Nakamura, Toshikazu ^c   Jiang, Wen G ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b VELINDRE CANCER CENTRE   (United Kingdom)

^c OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Angiogenesis; HGF SF; MRC5; NK4; Prostate cancer

Indexed keywords

ANGIOGENESIS INHIBITOR; HEPATOCYTE GROWTH FACTOR ANTAGONIST; NK4; RECOMBINANT SCATTER FACTOR; SCATTER FACTOR; TUMOR MARKER; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CANCER INVASION; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; DRUG EFFECT; FEMALE; FIBROBLAST; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; IN VIVO STUDY; MOUSE; NONHUMAN; NUDE MOUSE; OSMOTIC MINIPUMP; PRIORITY JOURNAL; PROSTATE TUMOR; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR VOLUME;

ANIMALS; BETA-LACTAMASES; BLOTTING, WESTERN; CELL ADHESION; CELL DIVISION; CELL MOVEMENT; FEMALE; FIBROBLASTS; HEPATOCYTE GROWTH FACTOR; HUMANS; MALE; MICE; MICE, NUDE; MITOGENS; NEOPLASM INVASIVENESS; NEOVASCULARIZATION, PATHOLOGIC; PHOSPHOPROTEINS; PHOSPHORYLATION; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-MET; SURVIVAL RATE; TUMOR CELLS, CULTURED; TYROSINE;

EID: 0038505656     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.11220     Document Type: Article

References (40)

1. Nakamura T. Structure and function of hepatocyte growth factor. Prog. Growth Factor Res 1991;3:67-85.
2. Nishimura K, Kitamura M, Miura H, Nonomura N, Takada S, Takahara S, Matsumoto K, Nakamura T, Matsumiya K. Prostate stromal cell derived hepatocyte growth factor induces invasion of prostate cancer cell line DU145 through tumor stromal interaction. Prostate 1999;41:145-53.
3. Kuba K, Matsumoto K, Date K, Shimura H, Tanaka M, Nakamura T. HGF/NK4, a four-kringle antagonist of hepatocyte growth factor, is an angiogenesis inhibitor that suppresses tumor growth and metastasis in mice. Cancer Res 2000;60:6737-43.
4. Gmyrek GA, Walburg M, Webb CP, Yu HM, You X, Vaughan ED, Vande Woude G, Kundson BS. Normal and malignant prostate epithelial cells differ in their response to hepatocyte growth factor/scatter factor. Am J Pathol 2001;159:579-90.
5. Jiang WG, Hiscox S, Matsumoto K, Nakamura T. Hepatocyte growth factor/scatter factor, its molecular, cellular and clinical implications in cancer. Crit Rev Oncol Hematol 1999;29:209-48.
6. Nakashiro K, Okamoto M, Hayashi Y, Oyasu R. Hepatocyte growth factor secreted by prostate-derived stromal cells stimulates growth of androgen-independent human prostatic carcinoma cells. Am J Pathol 2000;157:795-803.
7. Naughton M, Picus J, Zhu X, Catalona WJ, Vollmer RT, Humphrey PA. Scatter factor-hepatocyte growth factor elevation in the serum of patients with prostate cancer. J Urol 2001;165:1325-8.
8. Pisters LL, Troncoso P, Zhau HE, Li W, Voneschenbach AC, Chung LWK. C-met protooncogene expression in benign and malignant human prostate tissues. J Urol 1995;154:293-8.
9. Tsarfaty I, Alvord WG, Resau JH, Altstock RT, Lidereau R, Bieche I, Bertrand F, Horev J, Klabansky RL, Keydar I, Vande Woude GF. Alteration of Met protooncogene product expression and prognosis in breast carcinomas. Analytic Quant Cytol Histol 1999;21:397-408.
10. Watanabe M, Fukutome K, Kato H, Murata M, Kawamura J, Shiraishi T, Yatani R. Progression linked overexpression of c-met in prostatic intraepithelial neoplasia and latent as well as clinical prostate cancers. Cancer Lett 1999;141:173-8.
11. Nakamura T, Nishizawa T, Hagiya M, Seki T, Shimonishi M, Sugimura A, Tashiro K, Shimizu S. Molecular cloning and expression of human hepatocyte growth factor. Nature 1989;342:440-3.
12. Patthy L, Trexler M, Vali Z, Banyai L, Varadi A. Kringles: modules specialized for protein binding. Homology of the gelatin-binding region of fibronectin with the kringle structures of proteases. FEBS Lett 1984;171:131-6.
13. Lerch PG, Rickli EE, Lergier W, Gillessen D. Localization of individual lysine-binding regions in human plasminogen and investigations on their complex-forming properties. Eur J Biochem 1980;107: 7-13.
14. van Zonneveld AJ, Veerman H, Pannekoek H. On the interaction of the finger and the kringle-2 domain of tissue-type plasminogen activator with fibrin. Inhibition of kringle-2 binding to fibrin by epsilon-amino caproic acid. J Biol Chem 1986;261:14214-8.
15. Matsumoto K, Takehara T, Inoue H, Hagiya M, Shimizu S, Nakamura T. Deletion of kringle domains or the N-terminal hairpin structure in hepatocyte growth factor results in marked decreases in related biological activities. Biochem Biophys Res Commun 1991;181:691-9.
16. Kuba K, Matsumoto K, Ohnishi K, Shiratsuchi T, Tanaka M, Nakamura T. Kringle 1-4 of hepatocyte growth factor inhibits proliferation and migration of human microvascular endothelial cells. Biochem Biophys Res Commun 2000;279:846-52.
17. Chan AM, Rubin JS, Bottaro DP, Hirschfield DW, Chedid M, Aaronson SA. Identification of a competitive HGF antagonist encoded by an alternative transcript. Science 1991;254:1382-5.
18. Parr C, Jiang WG. Hepatocyte growth factor activators, inhibitors and antagonists and their implication in cancer intervention. Histol Histopathol 2001;16:251-68.
19. Silvagno F, Follenzi A, Arese M, Prat M, Giraudo E, Gaudino G, Camussi G, Comoglio PM, Bussolino F. In vivo activation of met tyrosine kinase by heterodimeric hepatocyte growth factor molecule promotes angiogenesis. Arterioscler Thromb Vasc Biol 1995;15: 1857-65.
20. Cioce V, Csaky KG, Chan AM, Bottaro DP, Taylor WG, Jensen R, Aaronson SA, Rubin JS. Hepatocyte growth factor (HGF)/NK1 is a naturally occurring HGF/scatter factor variant with partial agonist/antagonist activity. J Biol Chem 1996;271:13110-5.
21. Jakubczak JL, LaRochelle WJ, Merlino G. NK1, a natural splice variant of hepatocyte growth factor/scatter factor, is a partial agonist in vivo. Mol Cell Biol 1998;18:1275-83.
22. Date K, Matsumoto K, Shimura H, Tanaka M, Nakamura T. HGF/AANK4 is a specific antagonist for pleiotrophic actions of hepatocyte growth factor. FEBS Lett 1997;420:1-6.
23. Date K, Matsumoto K, Kuba K, Shimura H, Tanaka M, Nakamura T. Inhibition of tumor growth and invasion by a four-kringle antagonist (HGF/NK4) for hepatocyte growth factor. Oncogene 1998;17:3045-54.
24. Parr C, Hiscox S, Nakamura T, Matsumoto K, Jiang WG. NK4, a new HGF/SF variant, is an antagonist to the influence of HGF/SF on the motility and invasion of colon cancer cells. Int J Cancer 2000;85:563-70.
25. Grant DS, Kleinman HK, Goldberg ID, Bhargava MM, Nickoloff BJ, Kinsella JL, Polverini P, Rosen EM. Scatter factor induces blood vessel formation in vivo. Proc Natl Acad Sci USA 1993;90:1937-41.
26. Sugawara J, Fukaya T, Murakami T, Yoshida H, Yajima A. Hepatocyte growth factor stimulated proliferation, migration, and lumen formation of human endometrial epithelial cells in vitro. Biol Reprod 1997;57:936-42,
27. Jiang WG, Hiscox SE, Parr C, Martin T, Matsumoto K, Nakamura T, Mansel RE. Antagonistic effect of NK4, a novel hepatocyte growth factor variant, on in vitro angiogenesis of human vascular endothelial cells. Clin Cancer Res 1999;5:3695-703.
28. Papetti M, Herman IM. Mechanisms of normal and tumor-derived angiogenesis. Am J Physiol Cell Physiol 2002;282:C947-C70.
29. Ribatti D, Vacca A, Nico B, De Falco G, Giuseppe Montaldo P, Ponzoni M. Angiogenesis and anti-angiogenesis in neuroblastoma. Eur J Cancer 2002;38:750-7.
30. Cao G, O'Brien CD, Zhou Z, Sanders SM, Greenbaum JN, Makrigiannakis A, DeLisser HM. Involvement of human PECAM-1 in angiogenesis and in vitro endothelial cell migration. Am J Physiol Cell Physiol 2002;282:C1181-C90.
31. St. Croix B, Rago C, Velculescu V, Traverso G, Romans KE, Montgomery E, Lal A, Riggins GJ, Lengauer C, Vogelstein B, Kinzler KW. Genes expressed in human tumor endothelium. Science 2000;289: 1197-202.
32. Carson-Walter EB, Watkins DN, Nanda A, Vogelstein B, Kinzler KW, St. Croix B. Cell surface tumor endothelial markers are conserved in mice and humans. Cancer Res 2001;61:6649-55.
33. Jiang WG, Puntis MC, Hallett MB. Monocyte-conditioned media possess a novel factor which increases motility of cancer cells. lnt J Cancer 1993;53:426-31.
34. Davies G, Jian WG, Mason MD. Matrilysin mediates extracellular cleavage of E-cadherin from prostate cancer cells: a key mechanism in hepatocyte growth factor/scatter factor-induced cell-cell dissociation and in vitro invasion. Clin Cancer Res 2001;7:3289-97.
35. Humphrey PA, Zhu X, Zamegar R, Swanson P, Ratliff TL, Vollmer RT, Day ML. Hepatocyte growth factor and its receptor (c-MET) in prostatic carcinoma. Am J Pathol 1995;147:386-96.
36. Liu Y, Michalopoulos GK, Zarnegar R. Molecular cloning and characterization of cDNA encoding mouse hepatocyte growth factor. Biochim Biophys Acta 1993;1216:299-303.
37. Maemondo M, Narumi K, Saijo Y, Usui K, Tahara M, Tazawa R, Hagiwara K, Matsumoto K, Nakamura T, Nukiwa T. Targeting angiogenesis and HGF function using an adenoviral vector expressing the HGF antagonist NK4 for cancer therapy. Mol Ther 2002;5:177-85.
38. Davies G, Cunnick GH, Mansel RE, Mason MD, Jiang WG. Levels of expression of tumor endothelial markers and their correlation with prognosis in patients with breast cancer. Breast Cancer Res Treat 2002;76:S48.
39. Parr C, Davies G, Nakamura T, Matsumoto K, Mason MD, Jiang WG. The HGF/SF-induced phosphorylation of paxillin, matrix adhesion, and invasion of prostate cancer cells were suppressed by NK4, an HGF/SF variant. Biochem Biophys Res Commun 2001;285:1330-7.
40. Tomioka D, Maehara N, Kuba K, Mizumoto K, Tanaka M, Matsumoto K, Nakamura T. Inhibition of growth, invasion, and metastasis of human pancreatic carcinoma cells by NK4 in an orthotopic mouse model. Cancer Res 2001;61:7518-24.